Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heron's Sustol Faces Competition With Narrower Label Than Expected

Executive Summary

Heron Therapeutics gained approval of its chemotherapy-induced nausea and vomiting drug Sustol (granisetron), but the company faces stiff competition and postmarketing requirements. Analysts, nonetheless, think the product has a bright future on the US market.


Related Content

Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer
Heron hammered over Sustol NDA resubmission delay
A.P. Pharma Puts Off APF530 Launch To 2014 After Another FDA Rejection


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts